TSHA vs URGN Stock Comparison
URGN currently leads TSHA in this stock comparison, with AIQ scores of 53 vs 35. The clearest difference is quality.
What is the main difference between TSHA and URGN?
URGN leads the current stock comparison as UroGen Pharma Ltd., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Taysha Gene Therapies, Inc. vs UroGen Pharma Ltd.
URGN leads
URGN leads by 18 AIQ points, primarily on Quality and Momentum, but the lead has narrowed from 30 points over 30 sessions.
Fragile: 2 of 4 evidence groups support URGN, its lead is narrowing, and its current signal state is conflicted.
Taysha Gene Therapies, Inc.
UroGen Pharma Ltd.
The Algovestiq AIQ Score currently favors URGN over TSHA, 53 versus 35 as of Nov 15, 2026. URGN's advantage is driven primarily by stronger quality and momentum. URGN also shows the weaker technical structure relative to its 50-day moving average. 2 of 4 covered evidence groups favor URGN today, and the comparison is rated Fragile on stability: only 2 of 4 covered evidence groups agree. URGN lead: Weakening — the AIQ differential moved from 30 to 18 points over 30 sessions.
Compare Taysha Gene Therapies, Inc. and UroGen Pharma Ltd. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare TSHA and URGN against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality37 vs 68URGN +31
- Momentum32 vs 40URGN +8
- Risk Resilience37 vs 40Even
2 of 4 evidence groups favor URGN. URGN’s edge is concentrated in quality and momentum.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Momentum +1, not enough on its own to move the overall score.
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.72x)
Largest factor move: Value +2, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 5 active signals are unchanged.
URGN's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — TSHA and URGN both carry a full feed there.
The central trade-off
URGN (UroGen Pharma Ltd.): the stronger current systematic profile, led by quality and momentum.
TSHA (Taysha Gene Therapies, Inc.): the counter-case, on technicals.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
URGNURGN on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
URGNURGN on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
URGNURGN on the Momentum factor, by 8 points.
Lower downside
TSHATSHA carries the lower 1-month annualized volatility.
Analyst upside
EvenAnalyst targets are level or not covered for both names.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | TSHA | URGN | Note |
|---|---|---|---|
| Implied upside to target | — | +121.5% | Level |
| Target dispersion | — | +6.9% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 13 | 8 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
2 of 4 covered evidence groups favor URGN. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | URGN | 35 vs 53 |
| Fundamentals | URGN | EPS growth 23.1% vs 89.3%; TTM ROE -11% vs 1.2%; gross margin 89.2% vs 91.4%; operating margin -29.4% vs -12.4% |
| Valuation | Not covered | Not covered |
| Technicals | TSHA | Price vs 50-day -8.7% vs -29.2%; vs 200-day -22.6% vs -17.4% |
| Risk Resilience | Even | Risk Resilience 37 vs 40 |
| Analyst expectations | Not covered | Not covered |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of TSHA and URGN and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is wide at 18 points. (supports the conclusion holding)
- Only 2 of 4 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on URGN.
How the comparison changed
120 daily snapshots · May 27 – Nov 13URGN lead: Weakening — the AIQ differential moved from 30 to 18 points over 30 sessions.
- Today
- URGN +18
- 35 vs 53
- 7 sessions ago
- URGN +24
- 33 vs 57
- 30 sessions ago
- URGN +30
- 33 vs 63
- 90 sessions ago
- URGN +18
- 52 vs 70
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
0 bullish / 3 bearish / 2 neutral
Only TSHA
- Death Cross Active — bearish, trend, long horizon (17.97%)
- ADX Trend Weakening — neutral, trend, medium horizon
- Downtrend Structure Active — bearish, trend, long horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.72x)
2 bullish / 1 bearish / 2 neutral, conflicted
Only URGN
- Golden Cross Active — bullish, trend, long horizon (16.77%)
- ADX Trend Strengthening — neutral, trend, medium horizon
- Keltner Channel Breakdown — bearish, volatility, short horizon
- RSI Oversold — bullish, momentum, short horizon
Both carry 1 more signal that do not separate them: ATR Expansion - Breakout Mode.
URGN leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -2.61%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.8%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1TSHA closes the Quality gap — currently 31 points behind, the largest single contributor to URGN's edge.
- 2TSHA's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3URGN's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once.
- 4The narrowing continues — the lead has already given back 12 points over 30 sessions, and a further 18-point move would eliminate URGN's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
URGN leads on balance| Metric | TSHA | URGN |
|---|---|---|
| Revenue growth (YoY) | 0% | 22.8% |
| EPS growth (YoY) | 23.1% | 89.3% |
| Gross margin | 89.2% | 91.4% |
| Operating margin | -29.4% | -12.4% |
| Return on equity (TTM) | -11% | 1.2% |
| Debt to equity | 0.15 | -1.57 |
Performance
URGN leads 4 of 6 windows| Metric | TSHA | URGN |
|---|---|---|
| 1 week (5 sessions) | -5.3% | 5.8% |
| 1 month (20 sessions) | 13.3% | -24.2% |
| 3 months (63 sessions) | -34% | -46.7% |
| 6 months (126 sessions) | -31.2% | -9% |
| Year to date | -25.5% | 11.8% |
| 1 year (252 sessions) | -6% | 4.1% |
Technicals
TSHA has the stronger structure| Metric | TSHA | URGN |
|---|---|---|
| RSI (14) | 44.7 | 28.7 |
| ADX (14) | 15.1 | 45.1 |
| Price vs 50-day | -8.7% | -29.2% |
| Price vs 200-day | -22.6% | -17.4% |
| Volatility (1M, annualized) | 61.5% | 79.4% |
Risk
Split| Metric | TSHA | URGN |
|---|---|---|
| Beta | 1.73 | 1.33 |
| Sharpe ratio | 0.32 | 0.39 |
| Sortino ratio | 0.5 | 0.56 |
| Max drawdown | -49.7% | -50.8% |
| Current drawdown | -41.3% | -47.9% |
| Annualized volatility | 70.7% | 61.9% |
| Value at risk (95%) | -6.5% | -5.5% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, TSHA or URGN?
On the Algovestiq AIQ Score, URGN is the stronger of the two as of Nov 15, 2026, scoring 53 against TSHA's 35. The edge comes from quality and momentum. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is TSHA or URGN the better buy right now?
URGN carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 2 of 4 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 2 of 4 covered evidence groups agree. Treat the lead as provisional.
Why does the AIQ Score favor URGN over TSHA?
The composite weights Quality, Value, Momentum and Risk Resilience. URGN leads Quality by 31 points; URGN leads Momentum by 8 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, TSHA or URGN?
Analyst price targets imply not covered upside for TSHA and +121.5% for URGN. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, TSHA or URGN?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, TSHA or URGN?
URGN on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, TSHA or URGN?
URGN on the Momentum factor, by 8 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, TSHA or URGN?
TSHA is the more resilient of the two, so the other name carries the higher downside risk. TSHA carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is TSHA more profitable than URGN?
URGN leads on the comparable margin measures — gross margin 89.2% vs 91.4%; operating margin -29.4% vs -12.4%; ttm roe -11% vs 1.2%.
Is URGN's lead over TSHA getting stronger or weaker?
URGN lead: Weakening — the AIQ differential moved from 30 to 18 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.
What would change the TSHA vs URGN verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: TSHA closes the Quality gap — currently 31 points behind, the largest single contributor to URGN's edge; TSHA's Death Cross Active resolves — a bearish trend rule currently active against it; URGN's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once; the narrowing continues — the lead has already given back 12 points over 30 sessions, and a further 18-point move would eliminate URGN's advantage entirely.
What do the current signals say about TSHA and URGN?
TSHA: 0 bullish / 3 bearish / 2 neutral. URGN: 2 bullish / 1 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on TSHA is Death Cross Active (bearish, long horizon). On URGN it is Golden Cross Active (bullish, long horizon).
Compare TSHA and URGN with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.